|
|
Article: Unmet needs in US asthma market.
- Article from:
- Pharma Marketletter
- Article date:
- March 31, 2003
CopyrightCOPYRIGHT 2003 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The unprecedented success of GlaxoSmithKline's Advair (fluticasone plus salmeterol), the first drug to combine a bronchodilator with a corticosteroid in the same inhaler device, has changed the US market landscape for asthma therapies, says a new report from Frost & Sullivan, which adds that sales of drug treatments for asthma could grow from $4.23 billion in 2002 to $5.52 billion in 2009.
Asthma's growing prevalence in the USA, coupled with the need for more effective, safer and convenient drugs, has created a high-demand market eager to adopt new-generation treatments, it says. As physicians become more com- fortable with Advair's long-term safety, few patient ...